X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Part D 101: Three charts show how the Medicare Part D program could be improved to work better for seniors and people with disabilities

By Gabby Migliara  |    April 27, 2022
In yesterday’s post, we learned how Medicare Part D works for seniors and people with disabilities. Unfortunately, Part D beneficiaries are increasingly facing higher out-of-pocket costs for the...   Read More

Analysis: States can help patients save nearly $1,000 annually on their medicines

By Reid Porter  |    April 21, 2022
According to a new Ipsos/PhRMA poll, most Americans — 82% — agree that lowering out-of-pocket costs for health care should be a top priority for policymakers. A good place to start in lowering these...   Read More

Veterans Affairs 101: Three charts show how the VA system differs from Medicare

By Gabby Migliara  |    March 11, 2022
The U.S. Department of Veterans Affairs (VA) primarily provides medical coverage for veterans who have experienced service-related disabilities. Its unique system was developed to meet the targeted...   Read More

Government price setting leaves behind families counting on new medicines

By Nicole Longo  |    February 23, 2022
Rather than pursuing policies that would actually address our broken insurance system and lower costs for patients – while protecting medical innovation – policymakers keep going back to the same,...   Read More

PhRMA submits comments urging CMS to withdraw coverage proposal

By Lauren Neves  |    February 11, 2022
In comments submitted this week, PhRMA urged the Centers for Medicare & Medicaid Services (CMS) to withdraw its proposed national coverage determination (NCD) for monoclonal antibodies (mAbs) for the...   Read More

Medicaid 101: Three charts on access and spending

By Jasmine Gossett  |    February 3, 2022
Did you know Medicaidand the Children’s Health Insurance Program provide health coverage for more than 83 million vulnerable Americans, including children and their parents, pregnant women, the...   Read More

Government price setting won’t stop insurers from shifting costs to patients

By Nicole Longo  |    February 2, 2022
The drug pricing provisions in the Build Back Better Act (BBBA) would allow the government to set the price of certain medicines in Medicare. This is a misguided approach that threatens future...   Read More

New comments outline ways to counteract cost-shifting insurance trends

By Ashley Czin  |    January 28, 2022
PhRMA submitted comments this week in response to the Department of Health & Human Services’ (HHS) 2023 Notice of Benefit and Payment Parameters (NBPP) proposed rule. As outlined in our comments,...   Read More

New study finds more than half of brand medicine spending goes to the supply chain and others

By Brian Newell  |    January 7, 2022
More than half of total spending on brand medicines went to the supply chain, middlemen and other stakeholders in 2020 according to a new analysis from the Berkeley Research Group (BRG). These new...   Read More

Making medicines more affordable: Preserving safety-net programs like 340B

By Emilie Signora  |    December 17, 2021
Common-sense reforms can help ensure everyone benefits from America’s engine of innovation and receives the care they need and deserve. In this series, we’re taking a closer look at PhRMA’s advocacy...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates